PreMD Provides Update on 510(k) Application for PREVU* LT

    TORONTO, March 13 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; Amex:   PME) today announced that it has received feedback from the U.S.
Food and Drug Administration (FDA) regarding its 510(k) application for
PREVU(*) LT for use in the insurance industry. The FDA has additional inquiries
to which PreMD is responding. PreMD believes the specific matters raised by
the FDA are fully addressable and the Company plans to meet with the FDA at
the earliest opportunity to review the planned responses. PreMD submitted the
510(k) application to the FDA in November 2006.
    "We plan to work closely with the FDA to provide them with the
information they request. The agency has provided us with guidance as to the
specific information they require and we are diligently preparing our
response," said Dr. Brent Norton, President and Chief Executive Officer of
PreMD. "PREVU(*) LT has already been cleared for sale in Canada and CE marked in
Europe. This application is a priority for us and we anticipate that the
additional material will be submitted following the FDA meeting. Since the FDA
is already familiar with the application, the review could proceed more
rapidly than a typical 510(k)."

    About PREVU(*)LT
    PREVU(*) LT non-invasively measures the amount of cholesterol (sterol) that
has accumulated in the skin tissues, as opposed to blood, by painlessly
collecting skin cells from the palm of the hand using a specially designed
adhesive strip, which is then sent to a laboratory for processing. No fasting
or other patient preparation is required for the test. The lead product in
this family, PREVU(*) Point of Care (POC) Skin Sterol Test, is cleared for sale
in Canada, the U.S. and Europe.

    About PreMD
    PreMD Inc. is a world leader in predictive medicine, dedicated to
developing rapid, non-invasive tests for the early detection of
life-threatening diseases. PreMD's cardiovascular products are branded as
PREVU(*) Skin Sterol Test. The company's cancer tests include ColorectAlert(TM),
LungAlert(TM) and a breast cancer test. PreMD's head office is located in
Toronto, and its research and product development facility is at McMaster
University in Hamilton, Ontario. For further information, please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company
to take advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions.
    In addition, while the Company routinely obtains patents for its products
and technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.
    Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.

    (*) Trademark

    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Brent Norton, President and CEO, Tel: (416)
222-3449 ext. 22, Email:; Ron Hosking, Chief Financial
Officer, Tel: (416) 222-3449 ext. 24, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890